drugset / Trial / NCT07537049
BR101 in Patients With Relapsed/Refractory Multiple Myeloma
Phase 1
Not yet recruiting
10 enrolled
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Byterna Therapeutics Ltd. · collab
NaSingle-groupOpen-labelTreatment
Summary
This study is an open-label, single-arm, dose-escalation and dose-expansion clinical trial designed to evaluate the maximum tolerated dose, safety, pharmacokinetic profile following administration of BR101 injection, and preliminary efficacy in subjects with relapsed or refractory multiple myeloma.
Timeline
- Start
- 2026-04-30
- Primary completion
- 2027-04-30
- Completion
- 2029-04-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | BR101 | Cell therapy | — | Intravenous |